ARGX · argenx SE
$873.71
-0.23% last session
End-of-day data · close of 2026-10-23
Market cap
$55B
Enterprise value
$1,361B
Trailing P/E
30.3
Forward P/E
26.2
Dividend yield
0.0%
Beta
-0.04
Avg volume
0M
Employees
2K
Daily Change %
-0.23%
5 Days Change
6.91%
10 Days Change
9.11%
30 Days Change
-7.41%
60 Days Change
-13.39%
Month to Day Change
-6.44%
Year to Day Change
4.14%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ARGX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-23
Latest call per bank · past 12 months
Morgan Stanley
Overweight$1,190
+36.2% vs priceWells Fargo
Overweight$1,336
+52.9% vs priceRBC Capital
Outperform$1,025
+17.3% vs priceUBS
Buy$1,400
+60.2% vs priceCitigroup
Buy$1,182
+35.3% vs priceBank of America
Buy$1,088
+24.5% vs priceJP Morgan
Overweight$1,100
+25.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-23 | Morgan Stanley | Maintains | Overweight | $1,140 → $1,190 |
| 2026-10-23 | Guggenheim | Maintains | Buy | $1,185 → $1,120 |
| 2026-10-23 | Wells Fargo | Maintains | Overweight | $1,356 → $1,336 |
| 2026-10-23 | Evercore ISI Group | Maintains | Outperform | $1,078 → $1,090 |
| 2026-10-23 | Baird | Maintains | Neutral | $823 → $861 |
| 2026-10-20 | RBC Capital | Maintains | Outperform | $1,100 → $1,025 |
| 2026-10-14 | Wells Fargo | Maintains | Overweight | $1,355 → $1,356 |
| 2026-10-12 | Oppenheimer | Maintains | Outperform | $1,100 → $1,038 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 46 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 8.3% below the 50-day MA ($952.99).
- bullish: Price vs 200-day MA: Trading 2.5% above the 200-day MA ($852.51).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+5.82) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($663.93) and high ($1,058.90).
ARGX Price Chart
Loading chart for ARGX…
Fundamentals
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
GMAB
Genmab A/S
$27B 29.9% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.